Viemed Healthcare financials
$9.23+1.32%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $78.1M | $75.4M | $76.2M | $71.9M | $63.1M | $59.1M | $60.7M | $58.0M | $55.0M | $50.6M | $50.7M | $49.4M |
| Gross profit | $45.0M | $42.8M | $44.1M | $41.3M | $36.7M | $33.3M | $36.1M | $34.4M | $32.9M | $29.8M | $32.1M | $30.6M |
| Gross margin | 57.7% | 56.8% | 57.9% | 57.5% | 58.3% | 56.3% | 59.5% | 59.3% | 59.8% | 58.9% | 63.3% | 61.9% |
| Operating income | $5.0M | $4.6M | $8.6M | $6.1M | $4.4M | $1.4M | $5.3M | $4.9M | $3.6M | $2.4M | $5.6M | $4.4M |
| Net income | $2.8M | $2.6M | $5.6M | $3.5M | $3.2M | $2.6M | $4.3M | $3.9M | $1.5M | $1.6M | $3.5M | $2.9M |
| Net margin | 3.5% | 3.4% | 7.4% | 4.9% | 5.0% | 4.4% | 7.1% | 6.7% | 2.7% | 3.2% | 6.9% | 5.9% |
| Diluted EPS | $0.07 | $0.06 | $0.14 | $0.09 | $0.08 | $0.06 | $0.10 | $0.10 | $0.04 | $0.04 | $0.09 | $0.07 |
| EBITDA | $12.5M | $12.2M | $16.2M | $13.6M | $11.3M | $8.0M | $11.6M | $11.3M | $9.9M | $8.7M | $5.6M | $10.4M |
| Operating cash flow | $15.9M | $8.1M | $18.4M | $18.4M | $12.3M | $2.9M | $15.0M | $12.7M | $10.2M | $1.2M | $13.3M | $13.8M |
| Free cash flow | $7.4M | $1.4M | $9.7M | $10.7M | $4.1M | -$12.6M | $2.2M | $1.7M | $1.2M | -$4.8M | $5.3M | $6.4M |
| Diluted shares | 41.1M | 40.5M | 40.1M | 40.5M | 41.1M | 41.6M | 41.3M | 40.8M | 40.6M | 40.6M | 40.4M | 40.4M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $10.7M | $9.8M | $13.5M | $11.1M | $20.0M | $10.2M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $7.1M | $9.2M | $12.4M | $21.1M | $4.3M | $4.0M |
| Total assets | $204.2M | $197.4M | $199.2M | $202.4M | $184.6M | $178.1M |
| Total liabilities | $58.3M | $51.6M | $55.6M | $66.9M | $43.0M | $41.3M |
| Shareholders' equity | $146.0M | $145.8M | $143.5M | $135.5M | $141.6M | $136.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology